| scholarly article | Q13442814 |
| P50 | author | Sherry A McKee | Q92194846 |
| Jeanette M. Tetrault | Q113470629 | ||
| Marina Picciotto | Q40057362 | ||
| Suchitra Krishnan-Sarin | Q47498682 | ||
| P2093 | author name string | Julia Shi | |
| Stephanie S O'Malley | |||
| Ismene L Petrakis | |||
| Emily L R Harrison | |||
| Erika Balchunas | |||
| Naralys Estevez | |||
| P2860 | cites work | Varenicline: an alpha4beta2 nicotinic receptor partial agonist for smoking cessation | Q28250054 |
| Nicotine activation of alpha4* receptors: sufficient for reward, tolerance, and sensitization | Q28588299 | ||
| Suppression of ethanol-reinforced behavior by naltrexone is associated with attenuation of the ethanol-induced increase in dialysate dopamine levels in the nucleus accumbens. | Q48329536 | ||
| Voluntary ethanol intake in the rat and the associated accumbal dopamine overflow are blocked by ventral tegmental mecamylamine | Q48346302 | ||
| Signs and symptoms of tobacco withdrawal | Q49016637 | ||
| Mortality following inpatient addictions treatment. Role of tobacco use in a community-based cohort. | Q51036884 | ||
| Family history of alcoholism influences naltrexone-induced reduction in alcohol drinking. | Q51906284 | ||
| Involvement of nicotinic receptors in alcohol self-administration. | Q52170503 | ||
| Subjective responses to alcohol in sons of alcoholics and control subjects. | Q52272959 | ||
| The biological bases of nicotine and alcohol co-addiction. | Q52290406 | ||
| Assessment of medication compliance in alcoholics through UV light detection of a riboflavin tracer. | Q53964001 | ||
| SAFTEE: a technique for the systematic assessment of side effects in clinical trials | Q69649764 | ||
| Voluntary ethanol intake in the rat: effects of nicotinic acetylcholine receptor blockade or subchronic nicotine treatment | Q71865726 | ||
| The mesolimbic dopamine-activating properties of ethanol are antagonized by mecamylamine | Q72723449 | ||
| Acetylcholine receptors containing the beta2 subunit are involved in the reinforcing properties of nicotine | Q28589593 | ||
| Varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, selectively decreases ethanol consumption and seeking | Q30502320 | ||
| Effect of transdermal nicotine replacement on alcohol responses and alcohol self-administration | Q33820862 | ||
| Smoking status as a clinical indicator for alcohol misuse in US adults | Q33848797 | ||
| Efficacy of varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs placebo or sustained-release bupropion for smoking cessation: a randomized controlled trial | Q33997418 | ||
| Nicotinic mechanisms involved in the dopamine activating and reinforcing properties of ethanol | Q34002764 | ||
| Alcohol, tobacco and obesity are synergistic risk factors for hepatocellular carcinoma | Q34554393 | ||
| Neurochemical and behavioral studies on ethanol and nicotine interactions | Q35690515 | ||
| Nicotine addiction and comorbidity with alcohol abuse and mental illness | Q36298360 | ||
| Nicotine and non-nicotine smoking cessation pharmacotherapies | Q36403207 | ||
| Co-occurring risk factors for alcohol dependence and habitual smoking: update on findings from the Collaborative Study on the Genetics of Alcoholism. | Q36764752 | ||
| Alcohol's actions on neuronal nicotinic acetylcholine receptors. | Q36764756 | ||
| Cancer risk associated with alcohol and tobacco use: focus on upper aero-digestive tract and liver. | Q36764761 | ||
| Varenicline, an alpha4beta2 nicotinic acetylcholine receptor partial agonist, vs sustained-release bupropion and placebo for smoking cessation: a randomized controlled trial. | Q38405712 | ||
| Combined pharmacotherapies and behavioral interventions for alcohol dependence: the COMBINE study: a randomized controlled trial. | Q38407349 | ||
| Evaluation of the brief questionnaire of smoking urges (QSU-brief) in laboratory and clinical settings | Q39420790 | ||
| Development and initial validation of a measure of drinking urges in abstinent alcoholics | Q39474611 | ||
| Ethanol-associated olfactory stimuli reinstate ethanol-seeking behavior after extinction and modify extracellular dopamine levels in the nucleus accumbens | Q41706616 | ||
| Chronic ethanol consumption by C57BL/6 mice promotes tolerance to its interoceptive cues and increases extracellular dopamine, an effect blocked by naltrexone | Q42454703 | ||
| Naltrexone decreases craving and alcohol self-administration in alcohol-dependent subjects and activates the hypothalamo-pituitary-adrenocortical axis. | Q43893915 | ||
| Mecamylamine modifies the pharmacokinetics and reinforcing effects of alcohol | Q43940291 | ||
| Effects of combined systemic alcohol and central nicotine administration into ventral tegmental area on dopamine release in the nucleus accumbens | Q43940320 | ||
| Role of different nicotinic acetylcholine receptors in mediating behavioral and neurochemical effects of ethanol in mice | Q44292703 | ||
| A clinical laboratory paradigm for evaluating medication effects on alcohol consumption: naltrexone and nalmefene | Q44374802 | ||
| Mecamylamine attenuates the subjective stimulant-like effects of alcohol in social drinkers | Q44453598 | ||
| Naltrexone effects on alcohol consumption in a clinical laboratory paradigm: temporal effects of drinking | Q44727564 | ||
| Varenicline in the routine treatment of tobacco dependence: a pre-post comparison with nicotine replacement therapy and an evaluation in those with mental illness | Q44834253 | ||
| Mecamylamine and ethanol preference in healthy volunteers | Q45227006 | ||
| Age at smoking onset and its association with alcohol consumption and DSM-IV alcohol abuse and dependence: results from the National Longitudinal Alcohol Epidemiologic Survey | Q45240544 | ||
| The smoking cessation medication varenicline attenuates alcohol and nicotine interactions in the rat mesolimbic dopamine system | Q46173380 | ||
| Voluntary ethanol intake increases extracellular acetylcholine levels in the ventral tegmental area in the rat. | Q46618419 | ||
| P433 | issue | 2 | |
| P407 | language of work or name | English | Q1860 |
| P921 | main subject | varenicline | Q411330 |
| P304 | page(s) | 185-190 | |
| P577 | publication date | 2009-02-27 | |
| P1433 | published in | Biological Psychiatry | Q4914961 |
| P1476 | title | Varenicline reduces alcohol self-administration in heavy-drinking smokers | |
| P478 | volume | 66 |
| Q33720707 | "Killing Two Birds with One Stone": Alcohol Use Reduction Interventions with Potential Efficacy in Enhancing Self-Control |
| Q54998102 | A Combination of Naltrexone + Varenicline Retards the Expression of a Genetic Predisposition Toward High Alcohol Drinking. |
| Q34552358 | A Critical Review of the Effects of Nicotine and Alcohol Coadministration in Human Laboratory Studies |
| Q30412161 | A double-blind, placebo-controlled trial assessing the efficacy of varenicline tartrate for alcohol dependence |
| Q34038943 | A human alcohol self-administration paradigm to model individual differences in impaired control over alcohol use. |
| Q36821304 | A preliminary investigation of varenicline for heavy drinking smokers |
| Q37602654 | A preliminary study on the effect of combined nicotine replacement therapy on alcohol responses and alcohol self-administration |
| Q34137278 | Activation of alpha4* nAChRs is necessary and sufficient for varenicline-induced reduction of alcohol consumption |
| Q34516895 | Acute effects of low and high dose alcohol on smoking lapse behavior in a laboratory analogue task |
| Q47182010 | Advances in Pharmacotherapy Development: Human Clinical Studies |
| Q34411076 | Alcohol use disorder: pathophysiology, effects, and pharmacologic options for treatment |
| Q91994135 | Alcohol, tobacco, and marijuana consumption is associated with increased odds of same-day substance co- and tri-use |
| Q104460866 | An integrated behavioural intervention combined with varenicline for heavy-drinking smokers: a randomized pilot study |
| Q38839642 | An overview of alcohol and tobacco/nicotine interactions in the human laboratory |
| Q36185892 | Assessing the effects of chronic sazetidine-A delivery on nicotine self-administration in both male and female rats |
| Q37698964 | Association of the CHRNA4 neuronal nicotinic receptor subunit gene with frequency of binge drinking in young adults |
| Q41636544 | Associations of rare nicotinic cholinergic receptor gene variants to nicotine and alcohol dependence |
| Q92189687 | Building better strategies to develop new medications in Alcohol Use Disorder: Learning from past success and failure to shape a brighter future |
| Q36781037 | CC4, a dimer of cytisine, is a selective partial agonist at α4β2/α6β2 nAChR with improved selectivity for tobacco smoking cessation. |
| Q37259110 | Chemistry and pharmacological studies of 3-alkoxy-2,5-disubstituted-pyridinyl compounds as novel selective α4β2 nicotinic acetylcholine receptor ligands that reduce alcohol intake in rats |
| Q36133717 | Cigarette smoking predicts differential benefit from naltrexone for alcohol dependence |
| Q38594528 | Clinical neuroscience of addiction: similarities and differences between alcohol and other drugs |
| Q34351761 | Cognitive control in alcohol use disorder: deficits and clinical relevance |
| Q34183988 | Cognitive enhancers in the treatment of substance use disorders: clinical evidence |
| Q35689017 | Combined varenicline and naltrexone treatment reduces smoking topography intensity in heavy-drinking smokers. |
| Q42149212 | Combining Varenicline (Chantix) with Naltrexone Decreases Alcohol Drinking More Effectively Than Does Either Drug Alone in a Rodent Model of Alcoholism. |
| Q36372867 | Critical needs in drug discovery for cessation of alcohol and nicotine polysubstance abuse |
| Q36877440 | Current insights into the mechanisms and development of treatments for heavy drinking cigarette smokers |
| Q41938714 | Developing a model of limited-access nicotine consumption in C57Bl/6J mice. |
| Q90308784 | Differential patterns of alcohol and nicotine intake: Combined alcohol and nicotine binge consumption behaviors in mice |
| Q52639267 | Differential regulation of alcohol taking and seeking by antagonism at α4β2 and α3β4 nAChRs. |
| Q36936258 | Effect of Lowering the Dose of Varenicline on Alcohol Self-administration in Drinkers With Alcohol Use Disorders |
| Q47275723 | Effect of Varenicline Combined With Medical Management on Alcohol Use Disorder With Comorbid Cigarette Smoking: A Randomized Clinical Trial |
| Q37059266 | Effect of Varenicline Combined with High-Dose Alcohol on Craving, Subjective Intoxication, Perceptual Motor Response, and Executive Cognitive Function in Adults with Alcohol Use Disorders: Preliminary Findings |
| Q50042559 | Effects of Varenicline Alone and in Combination With Low-dose Naltrexone on Alcohol-primed Smoking in Heavy-drinking Tobacco Users: A Preliminary Laboratory Study |
| Q36363819 | Effects of Varenicline on Neural Correlates of Alcohol Salience in Heavy Drinkers |
| Q94155051 | Effects of ethanol and varenicline on female Sprague-Dawley rats in a third trimester model of fetal alcohol syndrome |
| Q36963775 | Effects of sazetidine-A, a selective alpha4beta2 nicotinic acetylcholine receptor desensitizing agent on alcohol and nicotine self-administration in selectively bred alcohol-preferring (P) rats |
| Q43121435 | Effects of systemic nicotine, alcohol or their combination on cholinergic markers in the frontal cortex and hippocampus of rat. |
| Q49892752 | Effects of the nicotinic agonist varenicline, nicotinic antagonist r-bPiDI, and DAT inhibitor (R)-modafinil on co-use of ethanol and nicotine in female P rats |
| Q38732866 | Effects of varenicline on alcohol cue reactivity in heavy drinkers |
| Q38870727 | Effects of varenicline on alcohol self-administration and craving in drinkers with depressive symptoms |
| Q48124586 | Effects of varenicline on cognitive performance in heavy drinkers: Dose-response effects and associations with drinking outcomes |
| Q41808636 | Effects of varenicline on ethanol- and food-maintained responding in a concurrent access procedure |
| Q34940888 | Effects of varenicline on ethanol-induced conditioned place preference, locomotor stimulation, and sensitization |
| Q36319552 | Effects of varenicline on operant self-administration of alcohol and/or nicotine in a rat model of co-abuse |
| Q35429740 | Effects of varenicline on the reinforcing and discriminative stimulus effects of cocaine in rhesus monkeys |
| Q37766239 | Emerging drugs to treat alcoholism |
| Q33818913 | Ethanol consumption: how should we measure it? Achieving consilience between human and animal phenotypes |
| Q43195621 | Evaluation of guanfacine as a potential medication for alcohol use disorder in long-term drinking rats: behavioral and electrophysiological findings. |
| Q38856407 | Experimental psychopathology paradigms for alcohol use disorders: Applications for translational research |
| Q48666297 | Fatality following a suicidal overdose with varenicline |
| Q22242633 | Future pharmacological treatments for substance use disorders |
| Q36872261 | Gabapentin potentiates sensitivity to the interoceptive effects of alcohol and increases alcohol self-administration in rats |
| Q54205394 | Gene Editing Vectors for Studying Nicotinic Acetylcholine Receptors in Cholinergic Transmission. |
| Q34970821 | Ghrelin receptor (GHS-R1A) antagonism suppresses both alcohol consumption and the alcohol deprivation effect in rats following long-term voluntary alcohol consumption |
| Q36231851 | Guidelines for biological treatment of substance use and related disorders, part 1: Alcoholism, first revision |
| Q30441131 | How can we use our knowledge of alcohol-tobacco interactions to reduce alcohol use? |
| Q34205530 | Human laboratory paradigms in alcohol research. |
| Q35124169 | Incremental efficacy of adding bupropion to the nicotine patch for smoking cessation in smokers with a recent history of alcohol dependence: results from a randomized, double-blind, placebo-controlled study |
| Q90566716 | Influence of combined treatment with naltrexone and memantine on alcohol drinking behaviors: a phase II randomized crossover trial |
| Q62729760 | Longitudinal Findings from a Randomized Clinical Trial of Varenicline for Alcohol Use Disorder with Comorbid Cigarette Smoking |
| Q36724460 | Longitudinal associations between smoking cessation medications and alcohol consumption among smokers in the International Tobacco Control Four Country survey |
| Q28263028 | Mecamylamine - a nicotinic acetylcholine receptor antagonist with potential for the treatment of neuropsychiatric disorders |
| Q47667884 | Mecamylamine treatment for alcohol dependence: a randomized controlled trial. |
| Q30399710 | Mechanisms underlying sleep-wake disturbances in alcoholism: focus on the cholinergic pedunculopontine tegmentum |
| Q38718932 | Medications development for the treatment of alcohol use disorder: insights into the predictive value of animal and human laboratory models |
| Q47942161 | Medications for alcohol use disorders: An overview |
| Q58131549 | Missed opportunities to test the neuropsychiatric safety--and efficacy--of varenicline among smokers with substance use disorders |
| Q35911952 | Moderators of Varenicline Treatment Effects in a Double-Blind, Placebo-Controlled Trial for Alcohol Dependence: An Exploratory Analysis |
| Q30475871 | Modulation of ethanol consumption by genetic and pharmacological manipulation of nicotinic acetylcholine receptors in mice |
| Q34383928 | Motivation for alcohol becomes resistant to quinine adulteration after 3 to 4 months of intermittent alcohol self-administration |
| Q52684297 | Muscarinic M5 receptors modulate ethanol seeking in rats. |
| Q35091293 | N-methyl-D-aspartate receptor antagonism has differential effects on alcohol craving and drinking in heavy drinkers |
| Q38768062 | Naltrexone for the treatment of comorbid tobacco and pornography addiction |
| Q34809762 | Neuroimaging insights into the role of cortical GABA systems and the influence of nicotine on the recovery from alcohol dependence |
| Q37473457 | Neuronal nicotinic acetylcholine receptors as pharmacotherapeutic targets for the treatment of alcohol use disorders |
| Q34342747 | Neuronal nicotinic acetylcholine receptors: common molecular substrates of nicotine and alcohol dependence |
| Q36137598 | Neuronal nicotinic acetylcholine receptors: neuroplastic changes underlying alcohol and nicotine addictions |
| Q37722622 | Nicotine administration in the cholinergic basal forebrain increases alcohol consumption in C57BL/6J mice. |
| Q47960292 | Nicotine administration in the wake-promoting basal forebrain attenuates sleep-promoting effects of alcohol |
| Q35034473 | Nicotine and ethanol cooperate to enhance ventral tegmental area AMPA receptor function via α6-containing nicotinic receptors |
| Q24234860 | Nicotine receptor partial agonists for alcohol dependence |
| Q26472086 | Nicotine receptor partial agonists for alcohol dependence |
| Q52305793 | Nicotine-induced locomotor sensitization: pharmacological analyses with candidate smoking cessation aids. |
| Q35079043 | Nicotinic acetylcholine receptors containing the α4 subunit are critical for the nicotine-induced reduction of acute voluntary ethanol consumption |
| Q35850223 | Nicotinic acetylcholine receptors containing the α4 subunit modulate alcohol reward |
| Q35591662 | Nicotinic acetylcholine receptors containing α6 subunits contribute to alcohol reward-related behaviours |
| Q28087047 | Nicotinic receptor modulation to treat alcohol and drug dependence |
| Q26853630 | Novel therapeutic strategies for alcohol and drug addiction: focus on GABA, ion channels and transcranial magnetic stimulation |
| Q27324817 | Oral operant ethanol self-administration in the absence of explicit cues, food restriction, water restriction and ethanol fading in C57BL/6J mice |
| Q89402756 | Overcoming the "Valley of Death" in Medications Development for Alcohol Use Disorder |
| Q34661812 | Partial agonists of the α3β4* neuronal nicotinic acetylcholine receptor reduce ethanol consumption and seeking in rats |
| Q28655227 | Peripherally circulating ghrelin does not mediate alcohol-induced reward and alcohol intake in rodents |
| Q36294656 | Pharmacological Options for Smoking Cessation in Heavy-Drinking Smokers |
| Q37708082 | Pharmacological approaches to reducing craving in patients with alcohol use disorders |
| Q36684437 | Pharmacotherapy for alcohol use disorder: current and emerging therapies |
| Q43061723 | Pharmacotherapy of alcoholism - an update on approved and off-label medications |
| Q42583506 | Pilot safety evaluation of varenicline for the treatment of methamphetamine dependence |
| Q36039402 | Positive and negative effects of alcohol and nicotine and their interactions: a mechanistic review. |
| Q34359231 | Potential substrates for nicotine and alcohol interactions: a focus on the mesocorticolimbic dopamine system |
| Q51084128 | Promising pharmacogenetic targets for treating alcohol use disorder: evidence from preclinical models. |
| Q92501996 | Promoting activity of (α4)3(β2)2 nicotinic cholinergic receptors reduces ethanol consumption |
| Q36581617 | Recent Advances in Nicotinic Receptor Signaling in Alcohol Abuse and Alcoholism |
| Q41528453 | Relative potency of varenicline or fluvoxamine to reduce responding for ethanol versus food depends on the presence or absence of concurrently earned food |
| Q37400844 | Results from a pilot clinical trial of varenicline for the treatment of alcohol dependence |
| Q36821822 | Reward Anticipation Is Differentially Modulated by Varenicline and Nicotine in Smokers |
| Q28083649 | Risk of neuropsychiatric adverse events associated with varenicline: systematic review and meta-analysis |
| Q36342934 | Rodent models and mechanisms of voluntary binge-like ethanol consumption: Examples, opportunities, and strategies for preclinical research |
| Q37193626 | Rodent models for compulsive alcohol intake |
| Q28109507 | Role of appetite-regulating peptides in the pathophysiology of addiction: implications for pharmacotherapy |
| Q35690145 | Role of α6 nicotinic receptors in CNS dopaminergic function: relevance to addiction and neurological disorders |
| Q33855987 | SPECT imaging of nicotinic acetylcholine receptors in nonsmoking heavy alcohol drinking individuals |
| Q58100058 | State-of-the-art behavioral and pharmacological treatments for alcohol use disorder |
| Q34079637 | Study protocol for a non-inferiority trial of cytisine versus nicotine replacement therapy in people motivated to stop smoking |
| Q38685941 | Subjective Response to Alcohol as a Research Domain Criterion. |
| Q99581955 | Suicide Attempt in a 38-Year-Old Patient on Varenicline While Intoxicated With Alcohol |
| Q37942053 | The CHRNA5-A3-B4 gene cluster in nicotine addiction |
| Q91796599 | The Cholinergic System as a Treatment Target for Opioid Use Disorder |
| Q48305886 | The Corticotropin Releasing Factor Receptor 1 in Alcohol Use Disorder: Still a Valid Drug Target? |
| Q47442429 | The Effect of Varenicline on the Neural Processing of Fearful Faces and the Subjective Effects of Alcohol in Heavy Drinkers. |
| Q92297287 | The Interplay Between Subjective Response to Alcohol, Craving, and Alcohol Self-Administration in the Human Laboratory |
| Q47403081 | The Nicotinic α6-Subunit Selective Antagonist bPiDI Reduces Alcohol Self-Administration in Alcohol-Preferring Rats |
| Q37401674 | The effect of smoking on allogeneic transplant outcomes. |
| Q37404736 | The effects of varenicline on alcohol seeking and self-administration in baboons. |
| Q36892785 | The natural expression of individual differences in self-reported level of response to alcohol during ecologically assessed drinking episodes |
| Q34336464 | The nicotinic acetylcholine receptor partial agonist varenicline increases the ataxic and sedative-hypnotic effects of acute ethanol administration in C57BL/6J mice |
| Q47550611 | The nicotinic receptor drug sazetidine-A reduces alcohol consumption in mice without affecting concurrent nicotine consumption |
| Q33949792 | The predicted impact of reducing the nicotine content in cigarettes on alcohol use |
| Q34959736 | The role of impulsivity in the aetiology of drug dependence: reward sensitivity versus automaticity |
| Q35788371 | The role of varenicline on alcohol-primed self-administration and seeking behavior in rats |
| Q37514878 | The α5 neuronal nicotinic acetylcholine receptor subunit plays an important role in the sedative effects of ethanol but does not modulate consumption in mice |
| Q30442195 | The β2 nicotinic acetylcholine receptor subunit differentially influences ethanol behavioral effects in the mouse |
| Q37043526 | Treatment of tobacco dependence in people with mental health and addictive disorders |
| Q48004085 | Varenicline Reduces Alcohol Intake During Repeated Cycles of Alcohol Reaccess Following Deprivation in Alcohol-Preferring (P) Rats. |
| Q39196596 | Varenicline Reduces Context-Induced Relapse to Alcohol-Seeking through Actions in the Nucleus Accumbens |
| Q50235992 | Varenicline and GZ-793A differentially decrease methamphetamine self-administration under a multiple schedule of reinforcement in rats |
| Q38129470 | Varenicline and neuronal nicotinic acetylcholine receptors: a new approach to the treatment of co-occurring alcohol and nicotine addiction? |
| Q36687594 | Varenicline and nicotine enhance GABAergic synaptic transmission in rat CA1 hippocampal and medial septum/diagonal band neurons. |
| Q41862387 | Varenicline attenuates cue-induced relapse to alcohol, but not nicotine seeking, while reducing inhibitory response control. |
| Q34271996 | Varenicline decreases alcohol consumption in heavy-drinking smokers |
| Q33929766 | Varenicline decreases ethanol intake and increases dopamine release via neuronal nicotinic acetylcholine receptors in the nucleus accumbens |
| Q43188062 | Varenicline decreases nicotine but not alcohol self-administration in genetically selected Marchigian Sardinian alcohol-preferring (msP) rats. |
| Q34097966 | Varenicline effects on drinking, craving and neural reward processing among non-treatment-seeking alcohol-dependent individuals |
| Q34190097 | Varenicline for tobacco dependence: panacea or plight? |
| Q50088319 | Varenicline for tobacco-dependence treatment in alcohol-dependent smokers: A randomized controlled trial |
| Q40491939 | Varenicline for treatment of alcohol dependence: a randomized, placebo-controlled trial |
| Q35219810 | Varenicline in the treatment of alcohol use disorders |
| Q47676125 | Varenicline modulates ethanol and saccharin consumption in adolescent male and female C57BL/6J mice |
| Q30454909 | Varenicline potentiates alcohol-induced negative subjective responses and offsets impaired eye movements |
| Q88959955 | Varenicline treatment for methamphetamine dependence: A randomized, double-blind phase II clinical trial |
| Q47373861 | Varenicline versus nicotine patch with brief advice for smokers with substance use disorders with or without depression: effects on smoking, substance use and depressive symptoms |
| Q35046256 | Varenicline, a partial agonist at neuronal nicotinic acetylcholine receptors, reduces nicotine-induced increases in 20% ethanol operant self-administration in Sprague-Dawley rats |
| Q34167551 | Varenicline, low dose naltrexone, and their combination for heavy-drinking smokers: human laboratory findings. |
| Q35195302 | Varenicline, naltrexone, and their combination for heavy-drinking smokers: preliminary neuroimaging findings. |
| Q34157977 | Voluntary intravenous self-administration of alcohol detects an interaction between GABAergic manipulation and GABRG1 polymorphism genotype: a pilot study |
| Q36532722 | Α4β2 and α7 nicotinic acetylcholine receptor binding predicts choice preference in two cost benefit decision-making tasks |
Search more.